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The design, synthesis, conformational studies and binding aﬃnity for VEGF receptors of a collection of
linear and cyclic peptide analogues of the N-terminal α-helix fragments 13–25 of VEGF and 1–13 of
Vammin are described. Linear 13(14)-mer peptides were designed with the help of an AGADIR algorithm
and prepared following peptide solid-phase synthetic protocols. Cyclic peptide derivatives were prepared
on-resin from linear precursors with conveniently located Glu and Lys residues, by the formation of
amide linkages. Conformational analysis, CD and NMR, showed that most synthesized peptides have a
clear tendency to be structured as α-helices in solution. Some of the peptides were able to bind a
VEGFR-1 receptor with moderate aﬃnity. In addition to the described key residues (Phe17, Tyr21 and
Tyr25), Val14 and Val20 seem to be relevant for aﬃnity.
Introduction
Angiogenesis is crucial for normal generation of new blood
vessels, but it is also implicated in a number of pathological
conditions,1,2 such as cancer, rheumatoid arthritis, and diabetic
retinopathy.3,4 One of the key factors promoting angiogenesis is
the Vascular Endothelial Growth Factor (VEGF) able to induce
multiple biological actions of endothelial cells, like proliferation
and migration, as well as vascular permeability enhancement.5
VEGF, and particularly its predominant isoform VEGF165
(VEGF-A), exerts its pro-angiogenic action through its binding
to specific receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR).6–9
Recent studies have shown that both receptors are necessary
for human tumor growth and metastasis formation.7 Whilst
VEGFR-2 appears to be directly involved in pathological angio-
genesis, VEGFR-1 seems to work as a negative regulator of its
activity,7,10 although its implication in angiogenesis is clear.11
VEGFR-1 and 2 receptors contain seven extracellular Ig-like
domains connected by a single transmembrane helix to the
intracellular tyrosine kinase domain. Most of the therapeutic
strategies hitherto described are directed to the inhibition of
the tyrosine kinase activity of the VEGF receptors.12,13 There
are indeed several compounds with this profile that are in
advanced clinical trials for tumour angiogenesis treatment.
Four small molecule tyrosine kinase inhibitors have now been
approved by the FDA as anti-cancer agents – sunitinib, sorafe-
nib, pazopanib and axitinib. An alternative approach is to
disrupt VEGF–VEGFR interaction through neutralization of
VEGF by monoclonal antibodies.14–16 Bevacizumab is a huma-
nized recombinant monoclonal antibody approved in 2004 as
first line therapy for metastatic colorectal cancer, and was the
first antiangiogenic agent launched to the market for the treat-
ment of tumor angiogenesis. Additionally, diﬀerent com-
pounds have been described as inhibitors of the VEGF–VEGFR
interaction through the binding to either VEGF17 or
VEGFRs18,19 or co-receptors.20,21 Most of these compounds
have emerged from high throughput screening of peptide and
diverse small-molecule libraries. VEGF and its receptors rep-
resent one of the best validated signaling pathways in angio-
genesis,22 however very little attention has been paid to the
rational design of compounds to modulate the protein–protein
interactions involved in the molecular recognition between
VEGF and VEGFRs.23–29 In this respect, disruption of the
above-mentioned protein–protein interaction could be a valid
target for the search for inhibitors of angiogenesis. Muta-
genesis data indicated that the VEGF binding sites for
VEGFR-1 and VEGFR-2 receptors are very similar.30,31 Two
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main hot-spots have been identified at the interaction inter-
face between VEGF and these receptors. These are fragments
of VEGF17–25, located at the N-terminal and VEGF81–91, located
at loop 3.32–36 We have recently reported the preparation of
cyclic peptide analogues of the second of these two hot-spots,
VEGF81–91.
37,38 Molecular modeling and 1H NMR studies on
these peptides indicated a tendency to be structured around
the central β-turn of the VEGF81–91 β-hairpin and some of
them showed significant aﬃnity for VEGFR-1, thus supporting
the design of mimics of this fragment as a valid approach to
disrupt the VEGF–VEGFR-1 interaction.
Concerning the less explored N-terminal fragment of
VEGF17–25, D’Andrea and co-workers have reported a 15-mer
analogue of VEGF14–28 (Ac-KLTWMELYQLAYKGI-NH2) that
exhibits stable helical structure in solution, and pro-angio-
genic properties both in vitro and in vivo.39,40 More recently,
the same authors described the preparation of a new peptide
analogue (Ac-KLTWQELYQLKYKGI-NH2) that shows anti-angio-
genic properties.41 Both peptides bind to the membrane of
endothelial cells, as observed in cellular assays, but no
binding assays with isolated receptors were reported. Within
the VEGF-A fragment 17–25, a Phe17 residue has been ident-
ified as key for the interaction with VEGF receptors 1 and 2,
while Tyr21 and Tyr25 seem to be important for the stabiliz-
ation of the α-helical structure.34 Moreover, this fragment has
been also located at the interaction interface of VEGF and the
Fab fragment of the monoclonal antibody bevacizumab,42 and
some other antibodies and peptides.15,36
Vammin is a VEGF protein isolated from snake venom that
exhibits potent antiangiogenic activity both in vitro and in vivo,
and proved to be specific for the VEGFR-2 receptor in a surface
plasmon resonance (SPR) binding assay.43 In addition to
VEGF, Vammin could be also considered a source of peptide
analogues for VEGF–VEGFR modulators. The crystal structure
of Vammin, reported by Morita and co-workers, revealed high
structural similarities with VEGF-A,44 and these authors cen-
tered their structural studies particularly on the Vammin frag-
ment 69–80, which corresponds to VEGF81–91.
Based on all the above precedents, we describe herein our
eﬀorts towards the de novo design of helical peptides able to
mimic VEGF13–25 and Vammin1–13 fragments, selected as the
minimum sequence to maintain the native helix confor-
mation. Our main goal is to interfere with the VEGF–VEGFR
interaction and try to identify key elements driving the mole-
cular recognition between these two proteins. The small set of
designed peptides adopted the desired α-helical structures,
similar to those of the parent fragments in the native proteins,
as confirmed by CD and 1H NMR studies. Moreover, most of
them are able to interact with the VEGFR-1 receptor.
Results
Design
Fragments of VEGF-A (13–25) and Vammin (1–13), with helical
structure within the respective native protein, were taken as
models for the search for new modulators of the VEGF–VEGFR
interaction. For the design of VEGF13–25 analogues, key amino
acids Phe17, Tyr21 and Tyr25 (corresponding to residues 5, 9
and 13 in the designed peptides) were maintained while the
other residues were replaced. Alignment of the N-terminal
regions of VEGF-A and Vammin permitted the identification of
the fragment 1–13 of Vammin as the sequence corresponding
to the VEGF13–25 fragment. In this case, residues Phe5, His9,
and Ala13, located at the equivalent positions identified as key
in VEGF13–25, were kept intact and only the rest of the residues
were modified. From the indicated fragments, virtual collec-
tions of linear peptides were generated by replacing each of
the modifiable residues by the 20 proteinogenic amino acids.
Then, we examined the helical character of each virtual
peptide using an AGADIR10 algorithm.45
Residues that increased the helical character of the peptide
were then combined to create a second-generation virtual
library. From this virtual collection, two peptides were chosen
to be prepared: one analogue of VEGF13–25, compound 2, and
one of Vammin1–13, 6 (Fig. 1). According to AGADIR prediction,
these analogues have higher tendency to adopt helical confor-
mations (≥60%), than the native sequences 1 and 5 (Fig. 1). An
important issue regarding purification as well as confor-
mational and biological studies of peptides is their aqueous
solubility. Taking into account that modifications to increase
helicity are often associated with a decrease in solubility, four
new peptide analogues (3, 4, 7 and 8), which contain more
polar residues (Ser), were selected. These peptides presumably
would be slightly more soluble in aqueous media than the pre-
vious analogues, as estimated by their log S values (calculated
by the AlOGPS 2.1 program),46,47 while still maintaining a
good predisposition to adopt helical conformations.
In addition, compounds 10 and 12, two constrained cyclic
peptide analogues of VEGF13–25, were designed (Fig. 2). In this
case, the strategy to fix the α-helix involved crosslinking amino
acid side-chains at relative positions i and i + 4, corresponding
either to residues 3 and 7 (A) or 7 and 11 (B) of the peptide,
situated at the opposite face to that containing the residues
reported as important for the molecular recognition. The
cyclization was performed through the generation of
Fig. 1 Sequences of VEGF13–25, Vammin1–13 and designed analogues 1–8.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2013 Org. Biomol. Chem., 2013, 11, 1896–1905 | 1897
Pu
bl
ish
ed
 o
n 
18
 Ja
nu
ar
y 
20
13
. D
ow
nl
oa
de
d 
by
 C
en
tro
 d
e 
Qu
im
ica
 O
rga
nic
a L
ora
 T
am
ay
o (
CE
NQ
UI
OR
) o
n 1
3/1
0/2
01
4 0
9:0
5:3
0. 
View Article Online
covalent amide bridges from conveniently situated Glu and Lys
residues, leading to lactam constrained cyclic peptides.
This approach has been widely reported as a successful
strategy for the stabilization of helical conformations.48–50 For
comparative purposes, it is also planned to study linear precur-
sors 9 and 11.
Synthesis
The synthesis of the designed peptides (Fig. 1 and 2) was per-
formed in parallel, following solid-phase protocols, using a
Rink amide MBHA polystyrene resin and an Fmoc/tBu strategy.
To prevent aggregation problems, and to favor intramolecular
cyclization when required, a low load resin (0.34 mmol g−1)
was used. All compounds were isolated as C-terminal amides
and acetylated at the N-terminal.
Cyclic compounds 16 and 18 were prepared by formation of
a side-chain-to-side-chain glutamate–lysine amide linkage,
from linear precursors 15 and 17 respectively (Scheme 1). The
glutamic acid residue was always placed towards the N-term-
inal side of the peptide, because a Glu-X-X-X-Lys arrangement
promotes higher helicity than the opposite Lys-X-X-X-Glu
organization, as reported by Mills et al. for a series of poly-
arginine α-helical peptidomimetics.49 Glu and Lys side-chains
were conveniently protected with allyl and Alloc groups,
respectively, suitable for orthogonal deprotection before on-
resin cyclization. After N-terminal acetylation, and Pd-catalyzed
deallylation of the linear precursors 13 and 14, lactamization
was performed with the assistance of microwave irradiation,
using PyAOP as a coupling agent.51–53 15% TFE was used as a
cosolvent of DCE, to stabilize the helix conformation and to
facilitate the cyclization. The reaction was accomplished in 1 h
for both derivatives, leading to the corresponding cyclic com-
pounds. After cleavage from the resin final cyclic peptides were
isolated, lyophilized and purified by semipreparative HPLC in
good yields. Linear peptide analogues were obtained after a
sequence comprising Fmoc-deprotection, acetylation, removal
of allyl groups and final cleavage from the resin. The expected
peptides 9–12 were not isolated as such, but as sulphones,
compounds 15–18 (Scheme 1) due to overoxidation of the Met
side-chain.54 NMR and mass spectra data of the isolated com-
pounds agreed with the sulphone structure (ESI†).55
Conformational analysis by circular dichroism
The tendency of the designed peptides to adopt helical confor-
mations was first examined by circular dichroism (CD). CD
spectra of compounds 1–8, 15–18 in aqueous solution are
indicative of mainly disordered peptides. The helix popu-
lations estimated from the observed ellipticity ([θ]) at 222 nm
in water at 5 °C are less than 10% for all peptides, except for
peptides 4, 7, 16 and 18 with helix populations in the 10–25%
range. These results contrast with the helical percentages of
up to 30–65% predicted from the sequence by AGADIR. These
discrepancies arise, in part, from the low solubility shown
by most of the peptides, particularly, the most hydrophobic
(3 and 8), and from inaccurate estimations of peptide concen-
trations from UV absorption values, especially in the case of
the aromatic-lacking Vammin analogues, which translate into
inaccurate ellipticity values ([θ], see Methods). All peptides
become more helical in the presence of TFE, as shown by their
CD spectra that display the helix-characteristic double
minimum at 208 and 222 nm (Fig. 3 and S1–3†). This indi-
cated that the designed peptides have high tendency to be
helical in the appropriate environment.
NMR conformational studies
To get further details of the structures adopted by the VEGF
and Vammin analogues, we performed an NMR structural
study of the peptides. Taking into account that CD indicated
very low helical percentages for all the peptides in aqueous solu-
tion, together with their low solubility, we decided to study the
peptides in the presence of trifluoroethanol.
The VEGF and Vammin analogues were demonstrated to
adopt helical structures in the mixed TFE–H2O solvent by the
set of NOEs, which included the non-sequential helix-charac-
teristic dαN(i, i+3), dαN (i, i+4) and dαβ (i, i+3) NOEs (see NOE sum-
maries in Fig. S7–S9†). Some of these non-sequential NOE
cross-peaks are seen in the NOESY spectral region shown in
Fig. 4 for compound 2.
Further evidence to support the helical structure of the pep-
tides came from the 1Hα and
13Cα chemical shifts, which
depend on the ϕ and ψ dihedral angles.56 Thus, the profiles of
conformational shifts (Δδ = δobserved − δrandom coil, ppm; where
δrandom coil were taken from Wishart et al.57) presented for all
the peptides are characteristic of helical structures, i.e., nega-
tive values for the Hα protons (Fig. 5) and positive values for Cα
(Fig. S4–6†). The absolute values for the central residues are
larger than those at the N- and C-termini, which indicates
that, as commonly found in linear helical peptides (i.e. 6), the
helices are frayed at both ends. This fraying eﬀect is more
apparent at the N-terminus of compound 5, the native frag-
ment of Vammin, which is explained by the presence of a Pro
residue at position 4 (Fig. 1). This Pro probably distorts the ϕ
and ψ dihedral angles characteristic of α-helices and, prevents
the formation of the first H-bond of the helix, between this
residue and Glu1.
Apart from the fraying eﬀect, the magnitudes of the confor-
mational shifts diﬀer among the diﬀerent peptides (Fig. 5).
Fig. 2 Cyclic constrained VEGF13–25 peptide analogues 10 and 12, and the corres-
ponding linear precursors 9, 11.
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The larger the magnitudes, the more populated are the
helices. Based on the averaged ΔδHα- and ΔδCα-values (Fig. 5),
the peptides can be qualitatively ranked according to their
helical populations. Additionally, the percentages of helix
adopted for each peptide can be quantitatively estimated from
the averaged ΔδHα-values, as previously described58,59
(Table 1). Qualitatively, the ranking of the peptides in terms of
theoretical (Fig. 1) and experimental helicity is coincident. In
general, the peptides with larger helix populations show a
larger number of non-sequential NOEs.
To visualize the helices adopted by the studied peptides, we
performed structure calculations (see Experimental methods).
The resulting structures are well defined (the range of average
RMSD for backbone atoms is 0.1–0.4 Å; see Table ST13 in ESI†)
and, as deduced from analysis of chemical shifts (see above),
show some fraying at the ends (Fig. S10–11†). The C-termini
are generally better defined in the VEGF-A than in the
Vammin analogues. This is probably due to the interactions
between the aromatic residues F5/Y9/Y13, all at the same
helix face, being more stabilizing than the corresponding
Scheme 1 Synthesis of amide-bridged cyclic peptides 16 and 18. (a) 20% piperidine–DMF; (b) Ac2O, DIEA–DMF; (c) PhSiH3, Pd(PPh3)4, DCM; (d) TFA–EDT–H2O–TIS
(94 : 2.5 : 2.5 : 1); (e) PyAOP–HOAt, DIEA, DMF, 120°, MW.
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interactions (F5/H9/A13) in the Vammin analogues, as seen in
Fig. 6 for VEGF analogue 2 and Vammin analogue 8. Concern-
ing the N-termini, the helices of the VEGF-A analogues with a
better N-cap residue, such as the N-terminal Glu in peptides 1
and 2, are less frayed than other compounds, for example,
compounds 3 and 4 with two consecutive Ser residues at the
N-end (Table 1). Among the Vammin analogues, the most dis-
ordered at the N-terminus is peptide 5 with a Pro at position 4,
as deduced from conformational shifts (see above).
Concerning the bridged VEGF peptides 16 and 18 (Fig. 2),
the helices adopted by the two peptides with an i/i + 4 bridge
are more populated than their corresponding linear analogues
15 and 17, respectively, but, peptide 16 shows a lower helix
population than peptide 18.
Fig. 3 CD spectra for Vammin1–13 analogues 5–8, in 30% TFE–H2O at pH 5.5
and 5 °C.
Fig. 4 Selected NOESY spectral region for peptide 2 in 30% TFE–H2O at pH 5.5
and 5 °C. The intra-residual Hα-NH cross-peaks are labeled and the non-sequen-
tial dαN(i, i+3) and dαN(i, i+4) boxed. The sequential dαN(i, i+1) are not labeled.
Table 1 Helix populations estimated for peptides 1–8, 15–18 in 30% TFE at pH 5.5 and 25 °C from ΔδHα-values as described in Methods
Peptide 1 2 3 4 5 6 7 8 15 16 17 18
Av. ΔδHα (ppm) −0.20 −0.29 −0.26 −0.27 −0.14 −0.28 −0.23 −0.24 −0.23 −0.30 −0.22 −0.48
% Helix 51 74 67 69 36 72 59 62 59 77 56 100
Fig. 5 Histogram showing the ΔδHα values (ΔδHα = δobservedHα − δRCHα, ppm) as a
function of the sequence number for: (A) VEGF13–25 analogues 1–4, (B)
Vammin1–13 analogues 5–8, and (C) VEGF13–25 analogues 15–18.
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Binding aﬃnity for VEGFR-1
Synthesized peptides were evaluated for their ability to dis-
place biotinylated VEGF165, in a chemiluminescent assay
relying on competition between tested compounds and bioti-
nylated VEGF165 for binding to the extracellular domain of
recombinant VEGFR-128,60 (D1–D7, Table 2). Some of the best
compounds were selected for dose–response binding studies
on the D1–D3 domain of the VEGFR-1 receptor, the specific
domains for VEGF binding.
Some of the prepared peptides exhibited good inhibition
percentages. Thus, for VEGF analogues, the best results were
shown by cyclic peptides 16 and 18 together with their linear
parent compounds 15 and 17, while AGADIR-based designed
peptides, 2–4, did not show significant binding. Concerning
Vammin analogues, 5–8, the parent Vammin 1–13 native
sequence, 5, together with analogues 6 and 8, showed signifi-
cant aﬃnity for VEGFR-1, with values of the same order as
those found for the VEGF derivatives (Table 2).
Dose–response experiments to determine IC50 values for
most compounds that have shown significant aﬃnity for the
VEGFR-1 receptor were performed. Cyclic constrained VEGF
analogues 16 and 18 and their parent linear precursors, 9 and
17, showed good binding aﬃnities. Cyclic analogue 16 having
the conformational restriction closer to the N-terminus of the
sequence exhibited the best IC50 value found for this collection
of peptides (Table 2, Fig. 7).
Discussion and conclusions
A small collection of linear and cyclic peptide analogues (1–8,
15–18) of the fragment 13–25 of VEGF, previously identified as
a hot-spot of the VEGF–VEGFR interaction, and of the corres-
ponding fragment of Vammin, 1–13, have been designed and
synthesized by solid-phase techniques. NMR conformational
studies (chemical shift deviation and non-sequential NOE)
showed that, in TFE–H2O solution, these peptides adopted the
desired native-like helical conformation. In general, and as
expected, the designed peptides were more structured than the
parent compounds 1 and 5.
When evaluated as inhibitors of the VEGF–VEGFR inter-
action most peptides proved to bind to the VEGFR-1 receptor,
the VEGF cyclic analogue 16 exhibiting the best IC50 value. A
combined analysis of structural and biological results indi-
cated that to interact with VEGFR-1, the peptides needed to
have a certain tendency to be helical, but once a minimum
helical population is reached the aﬃnity of the peptides does
not increase with increments in helicity. Detailed comparison
Fig. 6 NMR lowest target function structures of VEGF analogue 2 (left) and
Vammin analogue 8 (right): backbone atoms are shown as ribbons. Side chains
are colored in red for the negatively charged residues, in blue for the positively
charged residues, in cyan for the polar residues, in magenta for the hydrophobic
residues (Val/Leu), and in green for the residues reported as key for the inter-
action with VEGF receptors. Hydrogen atoms are not shown. All the residues are
labeled and the N- and C-ends are indicated. Side chains of Val8 and Ala8 are
not seen because they lie behind the ribbon.
Table 2 Inhibitory potency of peptides 1–8, 15–18 on VEGFR-1. Displacement
assays
Compound Sequence
%Inhibitiona IC50
b(μM)ECD
1 Ac-EVVKFMDVYQRSY-NH2 20 ± 3 —
2 Ac-EVQKFLEVYLRLY-NH2 9 ± 7 —
3 Ac-SSQKFLEVYQRLYN-NH2 N/A
c —
4 Ac-SSQKFLEVYLRLYN-NH2 N/A
5 Ac-EVRPFLEVHERSA-NH2 46 ± 9 47 ± 6
6 Ac-DVRRFLEVHLRLA-NH2 62 ± 18 —
7 Ac-DLRAFLEQHLRSA-NH2 N/A —
8 Ac-SVRRFLEAHLRLA-NH2 42 ± 6 —
15 Ac-EVEKFM(O2)KVYQRSY-NH2 62 ± 15 95 ± 17
16 Ac-EV-c(NH-CO)3,7[EKFM(O2) K]
VYQRSY-NH2
56 ± 11 36 ± 9
17 Ac-EVVKFM(O2)EVYQKSY-NH2 74 ± 8 43 ± 9
18 Ac-EVVKFM(O2)-c(NH-CO)
7,11
[EVYQK]SY-NH2
53 ± 11 52 ± 6
a Activity corresponds to the percentage of biotinylated VEGF165
displaced by a concentration of peptide of 100 μM on the whole
extracellular domain (ECD, D1–D7) of VEGFR-1. b Inhibitory
concentration able to displace 50% binding of biotinylated VEGF165
on D1–D3 VEGFR-1. cN/A = no aﬃnity observed.
Fig. 7 Dose–response curves for peptides 5, 15–18 on VEGF-1 D1–D3 displace-
ment assays.
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among the sequences of the designed analogues and the
native VEGF17–25 and Vammin1–13 native sequences indicates
that the two N-terminal residues, Glu1 and Val2, of 1 and 5
could be directly participating in the VEGF–VEGFR interaction.
Thus, VEGF analogues 3 and 4, in which Val2 has been
replaced by a Ser, and Vammin analogue 7, in which it has
been replaced by Leu, showed no aﬃnity for the VEGFR-1
receptor. Although this last change is more conservative, the
concomitant replacement of Val8 by Gln in 7 could also con-
tribute to the lack of aﬃnity. This Val residue is in the same
face of the helix as key residues Phe17, Tyr21, suggesting the
importance of a hydrophobic region for the interaction. On
the other hand, the Glu1 residue may play a stabilizing role on
the helical structure, as it is able to form H-bonds between its
side chain and unpaired main-chain NH and CO groups of the
first turn. Accordingly, it can be replaced by residues with
N-cap properties as Ser or Asp (compare compound 5 with 6
and 8).61 In the case of peptides 3 and 4, the extra C-terminal
residue (Asn) might also be responsible for the drop in aﬃnity.
As for the inhibition value found for analogue 2 was not very
reliable, taking into account the low water solubility and the
high ability for aggregation shown by this peptide at the con-
centration used in the binding assay.
Cyclic constrained VEGF analogues 16 and 18 and their
parent linear precursors 15 and 17 showed good VEGFR-1
aﬃnity values. Linear peptides 15 and 17 showed 3–4 fold
increased aﬃnity for VEGFR-1 over the native fragment 1, and
a slightly higher helicity. Compound 15 encompasses two
radical, non-conservative changes: Val3 has been replaced by
Glu, and Asp7 by Lys, while in the case of peptide 17, the
changes are much more conservative: Asp7 by Glu and Arg11
by Lys. However, all these modifications improve the aﬃnity
for the receptor, suggesting that the original residues are not
very important for binding. Therefore, the improved aﬃnities
of 15 and 17 could be ascribed to the increased helical charac-
ter, since the formation of ionic bridges between Glu and Lys
residues could contribute to the stabilization of their helical
conformation (Table 2, Fig. 7).62 Cyclic analogues 16 and 18
also proved to have more helical character than the parent
compound 1, and more than linear precursors 15 and 17. As
already mentioned, cyclic peptide 16 is the best compound
within this collection in terms of aﬃnity for the VEGFR-1.
However, peptide 18, with higher helicity than 16, showed less
aﬃnity for the receptor. The masking of the basic character of
the Arg11 residue, by forming the lactam cycle, could be
responsible for the slight drop in aﬃnity observed for 18 com-
pared with its parent linear compound 17 that still has a basic
Lys residue at the place of Arg11. The results found for com-
pound 5, native sequence of Vammin, together with analogues
6 and 8, showing non-negligible IC50 values for binding with
VEGFR-1, suggest that the specificity of Vammin for VEGFR-2
versus VEGFR-143 seems not to rely on this part of the Vammin
molecule (Table 2, Fig. 7).
Compared with the previously prepared analogues of the
VEGF81–91 fragment,
37,38 it can be said that the aﬃnities found
for the helical peptides described here are slightly better. This
can be attributed to the fact that their spatial conformation
mimics better the helical conformation adopted by the parent
native fragments in the protein, while in the VEGF81–91 ana-
logues only the β-turn of the native β-hairpin was mimicked.
This is also in accordance with the improved ability to displace
the VEGFR-1–VEGF interaction observed for the helical 16–27
fragment of VEGF as compared to the VEGF61–68 sequence,
proving once more that the 16–27 helical fragment constitutes
a hot-spot in the VEGF–VEGFR-1 interaction.24
In summary, Vammin analogues 5, 6 and 8, and cyclic con-
strained VEGF-A derivatives 16 and 18 as well as their precur-
sors 15 and 17 were able to interfere with the process of
VEGF–VEGFR-1 recognition. Compound 16, one of the pep-
tides with higher helical character, showed the best IC50 value
in the binding assay. As a conclusion, it can be inferred that
VEGF13–25, corresponding to one of the identified hot-spots for
the VEGF–VEGFR interaction, and its homologue Vammin1–13,
can be taken as templates for the design of peptide mimics
able to interfere with the interaction of VEGF with its recep-
tors. The detailed analysis of the peptide sequences suggests a
role for Glu1, as a helix initiator, and for Val2 and Val8 resi-
dues as relevant for the interaction with VEGFR-1, likely being
important as a hydrophobic patch, together with Phe5, Tyr9,
Tyr13. In addition, the obtained results suggest that the speci-
ficity of Vammin for the VEGFR-2 receptor does not rely on the
N-terminal region of the molecule, although minor modifi-
cations in this fragment can lead to the loss of VEGFR-1
aﬃnity (i.e., compound 7). These results encourage us to
prepare more VEGF and Vammin analogues to selectively inter-
fere with the VEGF–VEGFR-1 or VEGF–VEGFR-2 interaction,
which can constitute interesting tools in pharmacology.
Experimental
Synthesis of linear and cyclic derivatives 1–8, 15–18. General
procedure
Resin bound peptides were synthesized by conventional Fmoc
solid-phase chemistry on an MBHA-Rink amide resin.
Resins were swollen in DCM/DMF/DCM/DMF (4 × 0.5 min).
All compounds were synthesized manually in parallel on resin,
following the Fmoc/tBu strategy, using Fmoc-Glu(OtBu)-OH,
Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Leu-
OH, Fmoc-Ile-OH, Fmoc-Met-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
His(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-
Pro-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-
OH, Fmoc-Ala-OH, Fmoc-Lys(Alloc)-OH or Fmoc-Glu(All)-OH
as required.
In each coupling step, the appropriate Fmoc amino acid
(1.5 equiv.) was treated with HOBt/DIC (1.5 equiv.) in anhy-
drous DMF or with HCTU/DIEA (2 equiv.). Couplings were
allowed to proceed at room temperature overnight or for 1 h,
respectively. The coupling eﬃciency was monitored by ninhy-
drin or chloranil test, and when necessary repeated with a
fresh portion of Fmoc-amino acid and the indicated coupling
reagents. After each coupling step, the Fmoc group was
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removed by treatment with 20% piperidine in DMF
(3 × 10 min). The resin was washed and drained with
DMF/DCM/DMF/DCM (4 × 0.5 min).
For amide bridge formation, after removing Alloc and OAll
protecting groups, the linear-resin-bound derivative (100 mg,
0.034 mmol) was treated with a solution of PyAOP (177 mg,
0.34 mmol), HOAt (46 mg, 0.34 mmol), DIEA (0.12 ml,
0.68 mmol) in anhydrous DMF (2 ml). The reaction was
allowed to proceed under microwave irradiation for 1 h until
ninhydrin test was negative. The resin was washed and
drained with DMF/DCM/DMF/DCM (4 × 0.5 min).
Before cleavage from the resin, all derivatives were acetyl-
ated by treatment with a mixture of Ac2O–DIEA in DMF
(4 × 10 min) and then washed with DMF and DCM. For cyclic
analogues, acetylation was performed before Alloc and OAll
deprotection prior to cyclization. Finally, the resin was treated
with the cleavage cocktail TFA–EDT–H2O–TIS (94 : 2.5 : 2.5 : 1)
for 5 h at room temperature. The filtrates were precipitated
from diethyl ether, centrifuged and lyophilised, and the result-
ing mixture was purified by reverse phase semipreparative
HPLC to obtain the peptides 1–8, 15–18 in high purities
(>98%, HPLC-MS data) and 1–9% overall yield (calculated on
the bases of resin substitution). See ESI† for details.
Circular dichroism spectroscopy
CD spectra were recorded on a Jasco J-810 instrument
equipped with a Peltier temperature control unit, at 5 °C both
in H2O and in 30% TFE–H2O solutions.
2D NMR spectroscopy
Samples were prepared by dissolving the lyophilized peptide
(∼1 mg) in 0.4 ml of H2O–D2O 9 : 1 v/v, adjusting the pH to 5.5
by adding minimal amounts of NaOD or DCl, and adding the
amount of deuterated TFE (0.17 ml) necessary to give a TFE/
water ratio of 30 : 70 in volume. Resulting peptide concen-
trations were about 1 mM. pH was measured with a glass
microelectrode and not corrected for isotope eﬀects. The temp-
erature of the NMR probe was calibrated using a methanol
sample. Sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS)
was used as an internal reference. NMR spectra were acquired
at 25 °C in a Bruker AV-600 spectrometer operating at a proton
frequency of 600.13 MHz and equipped with a cryoprobe. As
previously reported,63 phase-sensitive two-dimensional corre-
lated spectroscopy (COSY), total correlated spectroscopy
(TOCSY), nuclear Overhauser enhancement spectroscopy
(NOESY) spectra and 1H–13C heteronuclear single quantum
coherence spectra (HSQC) at natural 13C abundance were
recorded by standard techniques using presaturation of the
water signal and the time-proportional phase incrementation
mode. NOESY mixing times were 150 ms and TOCSY spectra
were acquired using 60 ms DIPSI2 with a z filter spin-lock
sequence. Acquisition data matrices were defined by 2018 ×
512 points in t2 and t1, respectively. Data were processed using
the standard TOPSPIN program.64 The 2D data matrix was
multiplied by either a square-sine-bell or a sine-bell window
function with the corresponding shift optimized for every
spectrum and zero-filled to a 2K × 1K complex matrix prior to
Fourier transformation. Baseline correction was applied in
both dimensions. The 0 ppm 13C δ-value was obtained
indirectly by multiplying the spectrometer frequency that
corresponds to 0 ppm in the 1H spectrum, assigned to an
internal DSS reference, by 0.25144953.65 Standard sequential
assignment methods66,67 were applied to assign the 1H NMR
signals of the peptides. Then, the 13C resonances were straight-
forwardly assigned based on the cross-correlations observed in
the HSQC spectra between the proton and the bound carbon
(1H and 13C chemical shifts for all the compounds are listed in
Tables ST1–ST12 as ESI†).
NMR structure calculation
Distance constraints were derived from the 2D 150 ms mixing
time NOESY spectra. The NOE cross-peaks were integrated by
using the automatic integration subroutine of the SPARKY
program68 and then calibrated and converted to upper-limit
distance constraints within the CYANA program. After cali-
bration, we excluded from the input list of distance constraints
those for which contribution of random conformations can
be large, i.e. intra-residual and sequential, except for the
dNHi–NHi+1, which are characteristic of helices and absent or
very weak in random conformations. ϕ and ψ angle restraints
were obtained from 1Hα,
13Cα and
13Cβ chemical shifts using
the TALOS program.69 The ϕ angles for those residues for
which the derived angle restraints were ambiguous were
restricted to the −180° to 0° range. A total of 50 structures
were calculated using the standard annealing strategy of the
CYANA program.70 The 20 structures with the lowest target
function values were selected and energy-minimised within
the CYANA program. The structures were examined using the
program MOLMOL.71
Chemiluminescent competition assays
The surface of a white high-binding 96-well microplate was
coated with 100 μl of phosphate-buﬀered saline solution (PBS,
pH 7.4) containing either VEGFR-1 D1–D3/Fc Chimera (20 ng
per well) or VEGFR-1 D1–D3/Fc chimera (15 ng per well) and
incubated at 4 °C overnight. After three washes with 250 μl of
PBS 0.1%, (v/v) Tween 20 (buﬀer A), the plate was blocked by
200 μl of PBS with 3% (w/v) of BSA and stirred at 37 °C for 2 h.
The plate was washed three times with buﬀer A. Then, 100 μl
of a solution of btVEGF165 at 131 pM (5 ng mL
−1) and the
tested compounds at various concentrations diluted in PBS
containing 1% DMSO were added to each well. After 3 h stir-
ring at 37 °C, the plate was washed four times with buﬀer A
and 100 μl of streptavidin–horseradish peroxidase diluted at
1 : 8000 in PBS containing 0.1% (v/v) Tween 20 and 0.3% (w/v)
BSA were added per well. After 1 h of incubation at 37 °C in
the dark and stirring, the plate was washed five times with
250 μl of buﬀer A and 100 μl of the chemiluminescent sub-
strate were added. The remaining bt-VEGF165 was detected by
chemiluminescence, which was quantified. The percentages of
btVEGF165 displacement were calculated by the following
formula: percentage of displacement = 100 × [1 − (S − NS)/
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(MS − NS)], where S is the signal measured, NS is the non-
specific binding signal and MS is the maximum binding
signal observed with btVEGF165 without compounds tested.
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